NCT05469360 - Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

September 11, 2026

Study Completion Date

January 2, 2028

Conditions

Alzheimer DiseaseMild Cognitive Impairment

Interventions

DRUG

NIO752

A single intrathecal (cerebrospinal) injection of NIO752 of Dose A

DRUG

NIO752

A single intrathecal (cerebrospinal) injection of NIO752 at dose B

DRUG

Matching placebo

A single intrathecal injection of matching placebo

DRUG

NIO752

Multiple intrathecal injections of NIO752 of Dose A

DRUG

NIO752

Two intrathecal injections of NIO752 at dose C

DRUG

NIO752

Single intrathecal injection of NIO752 at dose C

DRUG

Matching placebo

Two intrathecal injections of matching placebo

Trial Locations (10)

20520

COMPLETED

Novartis Investigative Site, Turku

31059

RECRUITING

Novartis Investigative Site, Toulouse

46017

RECRUITING

Novartis Investigative Site, Valencia

59037

RECRUITING

Novartis Investigative Site, Lille

70210

COMPLETED

Novartis Investigative Site, Kuopio

75013

RECRUITING

Novartis Investigative Site, Paris

08036

RECRUITING

Novartis Investigative Site, Barcelona

08041

RECRUITING

Novartis Investigative Site, Barcelona

221 85

COMPLETED

Novartis Investigative Site, Malmo

141 86

COMPLETED

Novartis Investigative Site, Stockholm